Vol. 3 No. 1 (2023)
Reimbursement Reviews

Tafasitamab (Minjuvi)

decorative image

Published January 19, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tafasitamab (Minjuvi), 200 mg single-use vial, 12 mg/kg body weight, IV infusion.
  • Indication: Indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem cell transplant.